Eribulin in Cancer Treatment

Eribulin in Cancer Treatment

Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic b...

Full description

Bibliographic Details
Main Authors:	Umang Swami, Umang Shah, Sanjay Goel
Format:	Article
Language:	English
Published:	MDPI AG 2015-08-01
Series:	Marine Drugs
Subjects:	breast cancer EMBRACE eribulin E7389 Halichondrin B Halaven™ microtubule inhibitor NSC 707389
Online Access:	http://www.mdpi.com/1660-3397/13/8/5016

Similar Items

Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer
by: Hibiki Udagawa, et al.
Published: (2023-01-01)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
by: Mikihiro Yoshie, et al.
Published: (2021-08-01)

Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial
by: F Sh Ahmetzanov, et al.
Published: (2014-09-01)

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin
by: Bahram Sharif-Askari, et al.
Published: (2023-03-01)

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma
by: Alessandro De Vita, et al.
Published: (2016-12-01)

Multifarious targets beyond microtubules—role of eribulin in cancer therapy
by: Priya Seshadri, et al.
Published: (2021-12-01)

Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
by: E V Artamonova
Published: (2017-09-01)

Eribulin and Confusion: A Previously Unknown Drug Side-Effect
by: Abu Baker Sheikh, et al.
Published: (2020-06-01)

Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01)

Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms
by: Hugo Passos Vicari, et al.
Published: (2022-12-01)

Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells
by: Mana Azumi, et al.
Published: (2022-12-01)

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
by: L V Bolotina, et al.
Published: (2016-09-01)

Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
by: Vera A Gorbunova, et al.
Published: (2019-03-01)

The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models
by: Leila Takahashi-Ruiz, et al.
Published: (2022-12-01)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
by: Renaud Sabatier, et al.
Published: (2021-03-01)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
by: Elena I. Kovalenko, et al.
Published: (2020-05-01)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
by: Sakura Iizumi, et al.
Published: (2017-12-01)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
by: Jean-David Fumet, et al.
Published: (2018-08-01)

Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
by: Petra J. Pederson, et al.
Published: (2021-06-01)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
by: Tremblay G, et al.
Published: (2016-09-01)

Efficacy of Eribulin in Soft Tissue Sarcomas
by: Edward Phillips, et al.
Published: (2022-03-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01)

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study
by: E. I. Kovalenko, et al.
Published: (2021-12-01)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
by: Ana López González, et al.
Published: (2022-11-01)

The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
by: Irina V Kolyadina, et al.
Published: (2019-06-01)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
by: Tsutomu Iwasa, et al.
Published: (2019-10-01)

Eribulin alongwith capecitabine in relapsed carcinoma breast- a retrospective single-Institutional study.
by: Soumita Poddar, et al.
Published: (2023-08-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells
by: Matteo Giulietti, et al.
Published: (2024-03-01)

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
by: Min Ho Park, et al.
Published: (2020-12-01)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
by: Hyemi Ko, et al.
Published: (2022-04-01)

Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types
by: Tamami Morisaki, et al.
Published: (2021-11-01)

Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study
by: Nicla La Verde, et al.
Published: (2022-10-01)

Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
by: Meng-Xia Su, et al.
Published: (2024-02-01)

New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
by: T Yu Semiglazova, et al.
Published: (2016-06-01)

Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment
by: Shinichiro Kashiwagi, et al.
Published: (2018-03-01)

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
by: Yu-Ju Lin, et al.
Published: (2021-06-01)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
by: Sarah S. Mougalian, et al.
Published: (2018-09-01)

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
by: Anne-Claire Hardy-Bessard, et al.
Published: (2020-12-01)

Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
by: Wataru Goto, et al.
Published: (2020-12-01)